Who are Korsana's investors?

Korsana's investors include Sanofi Ventures, TCG Crossover, Wellington Management, Venrock.

How much funding has Korsana raised?

Korsana has disclosed $325M raised across 2 rounds.

Where is Korsana headquartered?

Korsana is headquartered in Waltham, US.

Korsana

Waltham, US · 32 employees on LinkedIn · 7 known investors

Find your way into Korsana

Each arrow is one introduction. Sign up to fill in the first one.

233 people can intro you to Mark

Ask Meg Krench to introduce you to Mark Vignola

You →Meg · together at Korsana →Mark

65 people can intro you to Jonathan

Ask Jamie Chen to introduce you to Jonathan Violin

You →Jamie · together at Fairmount Funds Management LLC →Jonathan

Your email: who you already know at Korsana, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Korsana team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's. Its approach uses antibody engineering to enable therapies with meaningful central nervous system exposure delivered subcutaneously.

Biotech Deep Tech Healthtech

Founders & leadership

Mark Vignola Chief Financial OfficerMark Vignola is Chief Financial Officer of Korsana and holds a PhD in molecular biology with a background in biotechnology.

Jonathan Violin PresidentJonathan Violin is President of Korsana, which develops technology to deliver biologic drugs across the blood-brain barrier for neurodegenerative disease treatment. He has held CEO and board roles at biotech companies and has experience in drug discovery, scientific platform development, and capital raising.

Investors · 7

Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M

How we know: Sanofi Ventures's portfolio page · funding news · bioxconomy.com · the VCSheet dataset · Not right? Tell us

TCG Crossoverlisted by TCG CrossoverPalo Alto

Wellington Managementlisted by Wellington ManagementBoston · $5M – $50M

How we know: statnews.com · Not right? Tell us

VenrockreportedPalo Alto · $500K – $10M

How we know: statnews.com · Not right? Tell us

Also in the syndicate · 3

FairmountJ.P. Morgan Life Sciences Private CapitalTCGX

Funding

SEC filings, press & company announcements

$325M disclosed across 2 rounds · 2026

$150MSeries AFeb 2026
J.P. Morgan Life Sciences Private Capital, Sanofi Ventures, Wellington Management
Source ↗
$175MraisedFeb 2026 · 4 sources
Fairmount, TCGX, Venrock, Wellington Management
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

3 people who came through Korsana went on to found or lead other companies.

Jonathan ViolinPresidentFounded Viridian Therapeutics +1 Nimish ShahCo-Founder and Board DirectorFounded Apogee Therapeutics Andrew GottesdienerCo-Founder and Board MemberFounded Apogee Therapeutics

In the news

Korsana Biosciences Raises $175M in Fundingfinsmes.com · Feb 2026

Frequently asked questions

What does Korsana do?: Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's. Its approach uses antibody engineering to enable therapies with meaningful central nervous system exposure delivered subcutaneously.
Who are Korsana's investors?: Korsana's investors include Sanofi Ventures, TCG Crossover, Wellington Management, Venrock.
How much funding has Korsana raised?: Korsana has disclosed $325M raised across 2 rounds.
Where is Korsana headquartered?: Korsana is headquartered in Waltham, US.